Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis
Methotrexate (MTX) is a nonbiological disease-modifying antirheumatic drug that has shown both a good control of clinical disease and a good safety. Usually drug-drug interactions (DDIs) represent the most limiting factor during the clinical management of any disease, in particular when several drugs are coadministered to treat the same disease. In this paper, we report the interactions among MTX and the other drugs commonly used in the management of rheumatoid arthritis. Using Medline, PubMed, Embase, Cochrane libraries, and Reference lists, we searched for the articles published until June 30, 2012, and we reported the most common DDIs between MTX and antirheumatic drugs. In particular, clinically relevant DDIs have been described during the treatment with MTX and NSAIDs, for example, diclofenac, indomethacin, or COX-2 inhibitors, and between MTX and prednisone or immunosuppressant drugs (e.g., leflunomide and cyclosporine). Finally, an increase in the risk of infections has been recorded during the combination treatment with MTX plus antitumor necrosis factor- α agents. In conclusion, during the treatment with MTX, DDIs play an important role in both the development of ADRs and therapeutic failure.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2013 |
|---|---|
| Enthalten in: |
Advances in pharmacological sciences - 2013(2013) vom: 01., Seite 313858 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patanè, Marinella [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 06.06.2013 Date Revised 08.04.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1155/2013/313858 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM22807701X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM22807701X | ||
| 003 | DE-627 | ||
| 005 | 20231224075114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1155/2013/313858 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0760.xml |
| 035 | |a (DE-627)NLM22807701X | ||
| 035 | |a (NLM)23737767 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patanè, Marinella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.06.2013 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Methotrexate (MTX) is a nonbiological disease-modifying antirheumatic drug that has shown both a good control of clinical disease and a good safety. Usually drug-drug interactions (DDIs) represent the most limiting factor during the clinical management of any disease, in particular when several drugs are coadministered to treat the same disease. In this paper, we report the interactions among MTX and the other drugs commonly used in the management of rheumatoid arthritis. Using Medline, PubMed, Embase, Cochrane libraries, and Reference lists, we searched for the articles published until June 30, 2012, and we reported the most common DDIs between MTX and antirheumatic drugs. In particular, clinically relevant DDIs have been described during the treatment with MTX and NSAIDs, for example, diclofenac, indomethacin, or COX-2 inhibitors, and between MTX and prednisone or immunosuppressant drugs (e.g., leflunomide and cyclosporine). Finally, an increase in the risk of infections has been recorded during the combination treatment with MTX plus antitumor necrosis factor- α agents. In conclusion, during the treatment with MTX, DDIs play an important role in both the development of ADRs and therapeutic failure | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Ciriaco, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Chimirri, Serafina |e verfasserin |4 aut | |
| 700 | 1 | |a Ursini, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Naty, Saverio |e verfasserin |4 aut | |
| 700 | 1 | |a Grembiale, Rosa Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Gallelli, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a De Sarro, Giovambattista |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Emilio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in pharmacological sciences |d 2008 |g 2013(2013) vom: 01., Seite 313858 |w (DE-627)NLM204294444 |x 1687-6334 |7 nnns |
| 773 | 1 | 8 | |g volume:2013 |g year:2013 |g day:01 |g pages:313858 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1155/2013/313858 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2013 |j 2013 |b 01 |h 313858 | ||